0001209191-18-037472.txt : 20180613 0001209191-18-037472.hdr.sgml : 20180613 20180613163304 ACCESSION NUMBER: 0001209191-18-037472 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180611 FILED AS OF DATE: 20180613 DATE AS OF CHANGE: 20180613 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ANIDO VICENTE JR CENTRAL INDEX KEY: 0001207633 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36152 FILM NUMBER: 18897061 MAIL ADDRESS: STREET 1: 1621 BAYSIDE DR CITY: CORONA DEL MAR STATE: CA ZIP: 92625 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AERIE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001337553 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203109565 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7020 KIT CREEK ROAD STREET 2: SUITE 270 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-313-9650 MAIL ADDRESS: STREET 1: 7020 KIT CREEK ROAD STREET 2: SUITE 270 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-11 0 0001337553 AERIE PHARMACEUTICALS INC AERI 0001207633 ANIDO VICENTE JR C/O AERIE PHARMACEUTICALS, INC. 4301 EMPEROR BLVD., SUITE 400 DURHAM NC 27703 1 1 0 0 Chief Executive Officer Common Stock 2018-06-11 4 M 0 50000 3.15 A 176320 D Common Stock 2018-06-11 4 S 0 45004 61.9044 D 131316 D Common Stock 2018-06-11 4 S 0 4996 62.9203 D 126320 D Option (Right to Buy) 3.15 2018-06-11 4 M 0 50000 0.00 D 2017-09-12 2023-09-12 Common Stock 50000 846329 D The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $61.50 to $62.45, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $62.50 to $63.05, inclusive. /s/ Richard J. Rubino, Attorney-in-Fact for Vicente Anido, Jr. 2018-06-13